Doxorubicin liposomal - 2-BBB Medicines

Drug Profile

Doxorubicin liposomal - 2-BBB Medicines

Alternative Names: 2B3-101; Doxorubicin glutathione-pegylated liposome therapeutic - 2-BBB Medicines

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator to-BBB technologies
  • Developer 2-BBB Medicines
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; DNA topoisomerase III inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Glioma

Most Recent Events

  • 22 Sep 2016 Doxorubicin liposomal - 2-BBB Medicines is available for licensing as of 22 Sep 2016.
  • 22 Sep 2016 Phase-II development for Brain metastases and Glioma is ongoing (2-BBB Medicines pipeline, September 2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top